Perovskite-based Scintillator Material for X-ray Detection. We are a spinoff company from the National University of Singapore, working to build a new generation of X-ray detectors, which lowers X-ray exposure, increase scan rate and improve precision.
External link for Enlipsium
3 Research Link
Singapore, 117602, SG
Enlipsium reposted this
Great experience at American Society for Radiation Oncology (ASTRO) 2024! My key takeaway from the event is the critical role of enabling precision radiation therapy, both in terms of location and dosage. This advancement is essential for improving patient outcomes and minimizing side effects. #DeepTech #RadiationTherapy #AdvancedMaterials Enlipsium, Origgin Ventures Pte. Ltd.
Enlipsium reposted this
Had an incredible first day at American Society for Radiation Oncology (ASTRO) 2024! It was wonderful to reconnect with friends and colleagues dedicated to enhancing people’s health and well-being. I highly encourage everyone to visit the P-Cure Ltd booth, where they're showcasing the world’s first FDA cleared Proton Therapy system which can be installed in Linac Vaults. Udi Oren Michael Marash Enlipsium #DeepTech #Radiotherapy
Our CEO Yzhar Perry is gearing up for the Luminate Accelerator investor summit! #deeptech #photonics #advancedmaterials
Last week, our Luminate cohort 7 teams were in Rochester, engaging in investor pitches, visiting the AIM semiconductor facility in Albany, and having some well-deserved fun! Enjoy a day in the life with Luminate. Want to see more of the teams? Join us at Luminate Finals on September 26—register now to attend in person or watch online: https://lnkd.in/g8a5CEUF
Enlipsium is proud to be at the forefront of innovation, harnessing the power of light to enhance radiation therapies for cancer patients. Our cutting-edge optics technology aims to improve the precision and effectiveness of treatments, offering new hope to patients and healthcare providers alike. Read more about our groundbreaking work and its potential impact on the future of cancer therapy in this recent article by the Rochester Business Journal: Optics startup harnesses the power of light to improve radiation therapies for cancer patients. #Innovation #CancerTreatment #OpticsTechnology #Healthcare #Enlipsium #Dosimetry #RadiationTherapy https://lnkd.in/gxKJ3hYZ
We are incredibly proud to congratulate our partner and key inventor, Prof Liu Xiaogang, on being honored with the prestigious Royal Society of Chemistry Centenary Prize! 🏆 Prof Liu is the only researcher based in Asia and Singapore to receive this award out of three recipients globally this year. As one of the pioneering minds behind Enlipsium's technologies, Prof Liu's groundbreaking work on nanomaterials that convert X-rays/very high-energy X-rays into visible light has been instrumental in our development of cutting-edge solutions. His research has paved the way for our breakthroughs in dosimetry and X-ray imaging, with applications ranging from radiation therapy to non-destructive testing. Beyond his scientific contributions, Prof Liu has been an invaluable mentor and advisor to our technical team, guiding us with his expertise and vision. His dedication to pushing the boundaries of nanomaterial research has been a driving force behind our mission to develop innovative solutions that improve lives. Please join us in celebrating this remarkable achievement by Prof Liu Xiaogang. We are honored to have him as an integral part of the Enlipsium family, and we look forward to his continued leadership in shaping the future of nanomaterial applications.
Prof Liu Xiaogang from the NUS Department of Chemistry has been honoured with the prestigious Royal Society of Chemistry Centenary Prize for his outstanding research in photon conversion in nanocrystals and their applications in X-ray and light-field imaging. He is the only researcher based in Asia and Singapore to receive the award out of three recipients this year. #NUSExcellence #RSCPrizes National University of Singapore, Faculty of Science One of Prof Liu’s most notable contributions is the development of new nanomaterials that glow in visible colours when exposed to invisible near-infrared light. These materials could serve as advanced molecular probes that can track cancer cells, offering a more selective, sensitive, and cost-effective alternative to traditional biomarkers for cancer diagnosis. #NUSResearch #NUSImpact
Enlipsium's commitment to innovation and excellence has been recognised by Luminate NY, a leading accelerator program supporting startups in the optics, photonics, and imaging industries. Being chosen among a pool of remarkable startups is a testament to our dedication to improving cancer treatments through better dosimetry systems for radiation therapy. This opportunity is especially significant for us as it marks our entry into the US market. The validation of our product by esteemed industry leaders and experts through Luminate Accelerator NY reaffirms our belief in the transformative potential of our dosimetry systems, especially in the context of high-energy radiation therapy for cancer treatment. We're excited to bring our innovative solutions to the forefront and address the evolving needs of patients and healthcare professionals in the US market. We're eager to leverage Luminate NY's invaluable resources, mentorship, and funding to accelerate our growth trajectory. Collaborating with industry experts, investors, and fellow entrepreneurs will undoubtedly fuel our journey towards success. Together, we'll continue to revolutionise the cancer treatment landscape with cutting-edge technology and make a lasting impact on patient outcomes. NextCorps, Sujatha Ramanujan, Veronica LoCurcio, Damon Diehl. #DeepTech #Innovation #Photonics #Optics #Imaging #Entrepreneurship #TechStartup #EmpireStateDevelopment #AcceleratorProgram #MilestoneAchievement https://lnkd.in/gTJ__ji3
Enlipsium has been selected as one of the eight tech startups to pitch for a groundbreaking $5 million funding opportunity at the upcoming Future of Capitalism Competition! 🎉 A huge congratulations to all the finalists: Vocadian, Re-Fresh Global, DANNCE.ai, Hormony (Prelude Health), Dapio, CloudFO, and edulis. We're honored to be part of such a prestigious lineup of innovative companies! 🚀 Our team at Enlipsium is passionate about revolutionizing the #Medtech landscape, and being recognized as a finalist is a testament to our dedication and hard work. We can't wait to showcase our vision on pitch day, scheduled for 8 February. A special shoutout to the Leo Lion Team and esteemed judges, your support and expertise are invaluable to the growth of tech startups like ours! 👏 Stay tuned for updates as we prepare for this exciting opportunity, and thank you to everyone who has been a part of our journey so far. Let's make waves in the realms of Medtech, Dosimetry & Medical Imaging! 🌐💡 #Enlipsium #FutureofCapitalism #TechStartups #Innovation #PitchDay #FundingOpportunity #medtech #radiationtherapy #materialsscience #HealthTech #TechInnovation, Origgin Ventures Pte. Ltd., NUS Graduate Research Innovation Programme (GRIP)
📢 Announcing the Tech startups selected to pitch for $5m funding! Congratulations to all the finalists selected to pitch for the first Future of Capitalism Competition. They are: Vocadian Re-Fresh Global DANNCE.ai Hormony (Prelude Health) Dapio CloudFO Enlipsium Edulis Global Nano Network Limited The Leo Lion Competition Team and judges look forward to meeting everyone at pitchday on 8 February. Christy Cardenas Charles ▫️ Delingpole Deniz Ucbasaran 👨💻 Alex Stephany Nina Ho Peter Hood Sylvana Q. Sinha, Esq. #healthtech #fintech #cleantech #AI #techstartups
🌟 Enlipsium is excited to be a Top 10 finalist in the EQT Impact Challenge! 🙏 We're deeply honoured to stand alongside Southeast Asia's most influential impact enterprises and incredibly grateful for the chance to share our vision with the world. 🏥 At Enlipsium, we're not just a startup; we're a Medtech innovator on a mission. Our groundbreaking technology is set to revolutionize Radiation Therapy by enhancing accuracy and precision. We believe in making a real difference by improving the effectiveness and safety of this vital treatment. 🚀 With EQT and our fellow finalists, we're ready to take on this challenge head-on. But, we can't do it alone. We're calling upon our amazing community for support to secure our spot in the finals! 🗳️ Voting is now open and runs until November 7th. Simply visit https://lnkd.in/d9eMwCNT to watch our pitch and cast your valuable vote for Enlipsium. 🌍 Let's unite to uplift the lives of cancer patients, one step at a time. Together, we can bring about a brighter and safer future! 💪🩺 #EQTImpactChallenge #Enlipsium #MedtechInnovation #VoteForChange
🌟Vote for the top 5 startups that will pitch in the EQT Impact Challenge Finals this December! The EQT Impact Challenge, a competition that highlights the top impact enterprises in Southeast Asia, is presented by EQT Group, e27 (Optimatic), The Edge Singapore, and EY. The winner of the challenge will be receiving EUR 100,000 in investment and 300 consultancy hours from EY to help scale their impact to another level. These startups have made it to the Top 10 in the EQT Impact Challenge. Now, it's time for YOU to help us pick the top 5 that will advance to the finals! Cellivate Technologies EcoWorth Tech Umami Bioworks Materials In Works Qarbotech Insectta Enlipsium Nousq Pte Ltd ImpacFat Full Circle Biotechnology Visit https://lnkd.in/d9eMwCNT to watch the pitches and vote for the top 5 innovators that deserve a spot in the finals in Singapore this December! 🗳️ Voting ends on November 7. #EQTImpactChallenge #VoteForChange